RC288
/ RemeGen
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 18, 2026
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=326 | Not yet recruiting | Sponsor: RemeGen Co., Ltd.
New P1/2 trial • Oncology • Solid Tumor
April 01, 2026
RemeGen received NMPA approval to begin Phase I/IIa trials of RC288, a bispecific ADC targeting PSMA and B7H3 in advanced solid tumors.
(TipRanks)
New P1/2 trial • Solid Tumor
1 to 2
Of
2
Go to page
1